"This initiative is all about supporting academic research. Most of these projects are at an early stage and significant development is still required. What we have established is a very promising foundation that I am confident will deliver advances in terms of approaches to treatment." Said Dr. Michael Hayden, President, Teva Global R&D and Chief Scientific Officer."There is a new spirit of collaboration, which I hope will ultimately lead to improvements for patients," said Prof. Daniel Offen, Head of the Neuroscience Laboratory at the Felsenstein Medical Research Center of Tel-Aviv University. "The NNE is supporting our research into a molecule that we have designed. This molecule can bind to the trigger of Huntington disease, potentially slowing down the progression of the disease – this would represent a major step forward in this currently untreatable disease." "The NNE is an exciting collaboration that creates synergy between basic science, started by universities and hospitals, with the knowledge and resources from industry," said Professor Edi Barkai, Neurobiology of Learning and Memory, the University of Haifa. "In our case this involves some very promising work to add some spark to neuronal responses which we believe may re-set the brain's ability to learn and retain memory." The National Network of Excellence in Neuroscience includes the following institutions: The Hebrew University, The Weizmann Institute, The Technion, Ben Gurion university, Tel Aviv University, Sourasky Medical Center, Sheba Medical Center, Rabin Medical Center, Bar Ilan University and the University of Haifa. About Teva Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.